BioLineRx and Hemispherian report GLIX1 brain PK/PD data and dose GLIX1-C101 fourth cohortNov 16Clinical readoutAllarity TherapeuticsBioLineRx, Ltd.Updated
Ovarian cancer vaccine trial completes; new Phase 1 vaccine study registered for healthy volunteersNov 16Weekly roundup, 2 itemsMerck & Co., Inc.pembrolizumab
Merck's KEYNOTE-057 bladder cancer trial ends with results posted; eight more registry updatesNov 13Weekly roundup, 9 itemsDaiichi SankyoMerck & Co., Inc.Updated
FDA adds pembrolizumab-chemo nod for biliary tract cancer; prior RCC, TMB-H actions standNov 10Regulatory decisionbelzutifanMerck & Co., Inc.Updated
FDA accelerated approval covers Padcev plus Keytruda in urothelial carcinomaNov 9Regulatory decisionenfortumab vedotinMerck & Co., Inc.
Evaxion presents new EVX-01 immune data at SITC, showing ex vivo T-cell detectionNov 6Clinical readoutBioNTech SEEvaxion Biotech A/SUpdated
Merck collaborator posts pancreatic cancer results; new MK-1045, COPD trial records surfaceNov 6Weekly roundup, 14 itemsDaiichi SankyoensifentrineUpdated
Cidara/Merck Phase 1 trial tests MK-1406 with Fluzone HD vaccine, recruitingNov 4Trial updateCidara Therapeutics, Incfluzone
Merck registers new MK-8644 psoriasis trial; RA and HIV/HPV vaccine trials continueOct 30Weekly roundup, 11 itemscabazitaxeldexamethasoneUpdated
Merck posts Q3 2026 results with oncology approvals and new sac-TMT regulatory filingOct 29Quarterly updateGilead SciencesMerck & Co., Inc.
FDA clears efficacy supplement for Merck's Keytruda QlexOct 22Regulatory decisionMerck & Co., Inc.pembrolizumab and berahyaluronidase alfa-pmph
Merck's KEYNOTE-522 posts results in triple negative breast cancer; new PAH study starts in IndiaOct 22Weekly roundup, 5 itemsMerck & Co., Inc.pembrolizumabUpdated
Merck registers Phase 3 ovarian cancer and COPD trials; GT103/Keytruda NSCLC trial results postedOct 16Weekly roundup, 5 itemsDaiichi SankyoensifentrineUpdated
Cidara's CD388 Phase 3 ANCHOR trial for flu prevention is recruiting, enrollment up to 10,000Oct 15Trial updateCidara Therapeutics, IncMerck & Co., Inc.
FDA approves supplement for Merck's Enflonsia (clesrovimab-cfor)Oct 14Regulatory decisionclesrovimabMerck & Co., Inc.
CTX-471 trial terminated after combo arm misses efficacy; two device trials await startOct 9Weekly roundup, 3 itemsCompass TherapeuticsCTX-471
Merck registers Phase 2b trial of tulisokibart for noninfectious uveitisOct 9Weekly roundup, 8 itemsglycopyrrolateMerck & Co., Inc.
Merck registers two new Phase 1/2 trials; KEYVIBE-005 results remain on recordOct 2Weekly roundup, 8 itemsdolutegravir sodium and lamivudinedoravirineUpdated
Merck posts two Phase 3 trials, sotatercept in HFpEF and sac-TMT in bladder cancerSep 24Weekly roundup, 4 itemsMerck & Co., Inc.sotatercept-csrk